Young Jonathan A, Jensen Elizabeth A, Stevens Austin, Duran-Ortiz Silvana, List Edward O, Berryman Darlene E, Kopchick John J
Edison Biotechnology Institute, Ohio University, Athens, OH, United States of America; Molecular and Cellular Biology Program, Ohio University, Athens, OH, United States of America.
Edison Biotechnology Institute, Ohio University, Athens, OH, United States of America; Heritage College of Osteopathic Medicine, Athens, OH, United States of America; Translational Biomedical Sciences Program, Graduate College, Ohio University, Athens, OH, United States of America.
Growth Horm IGF Res. 2019 Jun-Aug;46-47:5-15. doi: 10.1016/j.ghir.2019.05.001. Epub 2019 May 3.
Growth hormone (GH) has been reported to enhance the intestinal barrier; as such, recombinant GH has been administered for several intestinal diseases. However, excess GH action has been implicated in increasing the risk of intestinal dysfunction. The goal of this study was to examine the direct effects of GH on the small and large intestines to clarify the role GH plays in intestinal function through the use of a mouse model.
An intestinal epithelial-specific GH receptor (GHR) knockout (IntGHRKO) mouse line was generated using Cre-lox with the villin promoter driving Cre expression. The generated mice were characterized with respect to growth and intestinal phenotypes.
IntGHRKO mice showed no significant changes in body length, weight, or composition compared to floxed controls. Male IntGHRKO mice had significantly shorter large intestines at 4 and 12 months of age. Intestinal barrier function was assessed by measuring the expression of tight junction related genes, as well as levels of serum endotoxin and fecal albumin. Results showed sex differences as males had an increase in occludin levels but normal serum endotoxin and fecal albumin; while, females had changes in fecal albumin levels with normal occludin and serum endotoxin. Evaluation of glucose tolerance and fat absorption also showed sex differences as females were glucose intolerant, while males had impaired fat absorption. Histopathology revealed a trend towards decreased villus height in males, which could explain the sex difference in glucose homeostasis.
Overall, the data demonstrate that disruption of GH on the intestinal epithelial cells modestly affects the intestinal gross anatomy, morphology, and function in a sex-specific manner.
据报道,生长激素(GH)可增强肠道屏障;因此,重组生长激素已被用于治疗多种肠道疾病。然而,过量的生长激素作用与肠道功能障碍风险增加有关。本研究的目的是通过使用小鼠模型来研究生长激素对小肠和大肠的直接影响,以阐明生长激素在肠道功能中所起的作用。
利用Cre-lox技术,以绒毛蛋白启动子驱动Cre表达,构建了肠道上皮特异性生长激素受体(GHR)基因敲除(IntGHRKO)小鼠品系。对所产生的小鼠的生长和肠道表型进行了表征。
与对照小鼠相比,IntGHRKO小鼠的体长、体重或组成没有显著变化。雄性IntGHRKO小鼠在4个月和12个月大时大肠明显较短。通过测量紧密连接相关基因的表达以及血清内毒素和粪便白蛋白水平来评估肠道屏障功能。结果显示存在性别差异,雄性小鼠的闭合蛋白水平升高,但血清内毒素和粪便白蛋白水平正常;而雌性小鼠的粪便白蛋白水平发生变化,闭合蛋白和血清内毒素水平正常。对葡萄糖耐量和脂肪吸收的评估也显示出性别差异,雌性小鼠葡萄糖不耐受,而雄性小鼠脂肪吸收受损。组织病理学显示雄性小鼠绒毛高度有降低趋势,这可以解释葡萄糖稳态方面的性别差异。
总体而言,数据表明肠道上皮细胞中生长激素的破坏以性别特异性方式适度影响肠道大体解剖结构、形态和功能。